ReviewImmunotherapy2025
Allogeneic CAR-T cell therapy in autoimmune diseases.
Review in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From technological iteration to clinical breakthrough: advances of CAR-T cell therapy in autoimmune diseases.Annals of medicine · 2026Review
- Chimeric antigen receptor T-cell therapy in systemic lupus erythematosus: From B cell depletion to immune reprogramming.Journal of translational autoimmunity · 2026Review
- Engineering immune cell therapies for inflammatory bowel disease: from stem cells to CAR T cells.Nature reviews. Gastroenterology & hepatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging evidence demonstrates the potential efficacy of chimeric antigen receptor (CAR) T cells in autoimmune diseases. Currently, this therapy relies primarily on patient-derived autologous CAR-T cells. However, the application of autologous CAR-T cells is hindered by several limitations, such as high costs, time-consuming, and vulnerability to failure during the manufacturing process. Allogeneic CAR-T cells are genetically engineered T cells derived from healthy donors that hold great promise for expanding the accessibility of CAR-T cell therapy and may overcome the limitations of autologous CAR-T cells. Recent studies with small sample sizes have suggested the potential of allogeneic CAR-T cells in autoimmune diseases. These results have motivated researchers and physicians to further investigate the application of allogeneic CAR-T cells. In this review, we discuss the development of allogeneic CAR-T cells, current studies on CAR-T cell therapy for autoimmune diseases, and potential toxicities of allogeneic CAR-T cells. In addition, we discuss current challenges and future directions for implementing this therapy in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.